We can’t show the full text here under this license. Use the link below to read it at the source.
Short Communication: Reduced Nevirapine Concentrations Among HIV-Positive Women Receiving Mefloquine for Intermittent Preventive Treatment for Malaria Control During Pregnancy
Lower Nevirapine Levels in Pregnant Women with HIV Taking Mefloquine to Prevent Malaria
AI simplified
Abstract
Median nevirapine (NVP) concentrations were significantly lower in maternal plasma (1,597 ng/mL vs. 2,353 ng/mL) and cord plasma (2,038 ng/mL vs. 2,434 ng/mL) among women receiving mefloquine (MQ) compared to those receiving placebo.
- Approximately 44% of maternal and 42% of cord plasma samples had zidovudine (AZT), lamivudine (3TC), and NVP concentrations below the limit of detection.
- Only 4% of participants reported not using antiretroviral drugs (ARVs).
- Median concentrations of AZT and 3TC were not significantly lower in the MQ arm compared to the placebo arm.
- The results suggest that MQ may affect the metabolism of NVP in both mothers and infants.
- These findings indicate a need to assess potential interactions between antimalarials and ARVs in pregnant women.
AI simplified